Back to mobile site

Piper Sandler Reiterates Overweight Rating on Regeneron Pharma (REGN)

April 10, 2026 8:51 AM EDT Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $875.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login